Thalassemia Major Stem Cell Therapy
What is Thalassemia Major?
Thalassemia Major, also known as Cooley’s anemia, is a severe inherited blood disorder that affects the body’s ability to produce normal hemoglobin — the protein in red blood cells that carries oxygen throughout the body.
People with this condition suffer from chronic anemia, which often requires regular blood transfusions and iron chelation therapy to manage iron overload caused by transfusions.
Over time, repeated transfusions can lead to complications affecting the heart, liver, and endocrine system. Traditional treatments can manage symptoms, but they do not cure the disease.
Frequently Asked Questions
Is stem cell therapy a permanent cure for Thalassemia Major?
Yes — when performed successfully with a compatible donor, hematopoietic stem cell transplantation can permanently correct the defective gene responsible for Thalassemia Major.
What is the success rate of the treatment?
The success rate ranges from 80% to 90% in children with a matched sibling donor. Success rates are lower in adults or in cases with mismatched donors.
Who can be a donor?
Typically, a fully HLA-matched sibling is the ideal donor. However, haploidentical (half-matched) or unrelated donors can also be used in specialized centers.
How long does the recovery process take?
Full recovery may take 6 to 12 months, depending on the patient’s immune reconstitution and absence of complications.
Is the treatment safe?
Stem cell transplantation is a complex but clinically approved and well-studied medical procedure. When performed by experienced specialists, risks can be minimized and outcomes optimized.
Can adults with Thalassemia Major undergo stem cell therapy?
Yes, though younger patients generally have better outcomes. Adult patients can still benefit, particularly when other treatments are no longer effective.
What are the alternatives if no donor is available?
Emerging therapies such as gene therapy using autologous stem cells are being tested and have shown encouraging results in early trials.